# MK-1022-016 (NCT07060807)

> A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07060807
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Breast Neoplasms
- Interventions: Patritumab deruxtecan; Paclitaxel; Nab-paclitaxel; Capecitabine; Pegylated liposomal doxorubicin; Trastuzumab deruxtecan; Rescue Medication
- Enrollment: 1000
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on MK-1022-016 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mk-1022-016-nct07060807